The annual ASCO Meeting, held in Chicago, May 31-June 4, 2019, explored many issues related to oncology. Exciting developments in the field of early detection include Grail’s liquid biopsy test and data showing that Medicaid expansion helped detect more cases of ovarian cancer earlier, potentially saving lives. New treatments for pancreatic cancer cut progression risk ...
Senators have been busy in Washington this week crafting drug pricing reform packages and trying to work out a compromise with President Trump and his administration on various bills related to healthcare reform and drug pricing. New research in oncology sees FDA approval for a breakthrough treatment and the use of organoids in liver cancer ...
Although the Centers for Medicare and Medicaid Services gave the nod to CAR T-cell therapy, they’re still balking at paying for the treatment. This week, several articles in the Innovation Partners BioBlog look at how the nation’s health insurance industry, led by Medicare and Medicaid, are out of step with newer one-treatment and customized treatments. ...
Forty four states filed against a group of 20 drug makers this week include Teva Pharmaceuticals, Inc., claiming price fixing, collusions and more. Meanwhile, another report uncovered that hospitals often charge double and sometimes even triple to private insurers over what Medicare would pay for the same procedures. The Trump Administration takes aim at ‘surprise ...
This week’s Innovation Partners BioBlog looks at top stories from the world of pharmaceutical and healthcare news. Elderly people who survive the three most common types of cancer are at an increase for brain metastasis, according to a new report. The Trump Administration continues to push for the repeal of the Affordable Care Act. And ...
Discussions in the news this week circle around CAR-T payments, PBM rebates, and whether or not the Trump Administration will continue voluntary payment models. A new blockchain healthcare initiative demonstrates how the Internet of Things (IoT), blockchain, and healthcare can work together for improved tracking and outcomes. And the ESMO Breast Cancer Congress is underway ...
Is it time to give up on biosims as the answer to high drug prices? Some experts say yes with suggestions for greater savings. Other measures this week to lower healthcare costs include CMS allowing health insurers to implement copay accumulator programs, which are intended to encourage the use of generic drugs, as well as ...
Activity at the state and federal level this week is heating up in the fight against higher drug and healthcare costs. PBMs testified before federal lawmakers, who seemed uncertain of their role in the industry. The Montana Senate delayed the Medicaid bill, and Pennsylvania’s Attorney General filed a petition to attempt to force UPMC to ...
What should insurers consider when they revise their formularies? Is fee-for-service the answer to the future of healthcare? We look into these top stories and more in this week’s Innovation Partners BioBlog. Other stories this week include the expansion of the Muriad-AstraZeneca/Merck partnership, Western Connecticut Health Network and Health Quests’ partnership, and more. Departing FDA ...
This week’s Innovation Partners BioBlog comes to you a day later than our usual publication date and includes highlights of the AACR conference as well as an announcement from Memorial Sloan Kettering on a new study showing CAR T cell therapy results in metastatic lung and breast cancer as well as malignant pleural mesothelioma. Other ...
